|Year : 2021 | Volume
| Issue : 1 | Page : 75-82
|Yoga as a novel adjuvant therapy for patients with idiopathic inflammatory myopathies
Steve S Kong1, Thanh Pham2, Allyson Fortis3, Alpa Raval4, Neha Bhanusali5
1 Department of Medicine, Highland Hospital Alameda Health, Oakland Ca, USA
2 College of Behavioral and Community Sciences, University of South Florida, Tampa, FL, USA
3 College of Nursing, University of South Alabama, Mobile, AL, USA
4 Healing Arts Specialist Orlando Health UF Cancer Center, School of Integrative Yoga, Orlando, FL, USA
5 Department of Medicine, University of Central Florida, Orlando, FL, USA
Click here for correspondence address and email
|Date of Submission||09-Sep-2020|
|Date of Decision||03-Dec-2020|
|Date of Acceptance||07-Dec-2020|
|Date of Web Publication||05-Feb-2021|
| Abstract|| |
Context: Recent studies have demonstrated that physical activity is well tolerated by patients with idiopathic inflammatory myopathies (IIMs) and can have additional benefits as an adjuvant therapy to pharmacologic agents, especially if started early. To date, no studies have examined the effects of yoga on patients with IIMs. Aims: The aim of this study was to evaluate the effects of yoga on self-reported difficulty in performing activities of daily living (ADL) and muscle strength in patients with mild-to-moderate IIMs. Subjects and Methods: A longitudinal cohort study in which participants were assessed using the Myositis Activities Profile (MAP) and manual muscle testing (MMT) before and after the completion of an 8-week instructor-guided yoga course was performed. Statistical Analysis Used: Wilcoxon signed-ranked test was performed for statistical analysis. Results: The average posttreatment MAP scores of six participants demonstrated an increase of 2.51 points, while the average MMT score of four participants demonstrated an increase of 11 points. Conclusions: This study is the first study to date to examine the effect of yoga as an adjuvant complementary therapy for patients with IIM. Continued research should be done on the effect of yoga as an adjuvant therapy, for in addition to increase in muscle strength and ability to perform ADL, yoga may offer potential improvements in mood, mental health, and sleep.
Keywords: Health, myositis, quality of life, rheumatic disease, yoga
|How to cite this article:|
Kong SS, Pham T, Fortis A, Raval A, Bhanusali N. Yoga as a novel adjuvant therapy for patients with idiopathic inflammatory myopathies. Int J Yoga 2021;14:75-82
|How to cite this URL:|
Kong SS, Pham T, Fortis A, Raval A, Bhanusali N. Yoga as a novel adjuvant therapy for patients with idiopathic inflammatory myopathies. Int J Yoga [serial online] 2021 [cited 2023 Mar 22];14:75-82. Available from: https://www.ijoy.org.in/text.asp?2021/14/1/75/308742
| Introduction|| |
Idiopathic inflammatory myopathies (IIMs), such as polymyositis (PM) and dermatomyositis (DM), are rare yet potentially devastating autoimmune processes affecting approximately 10 in 100,000 globally. Clinical presentations of IIMs can vary widely, ranging from isolated mild muscle weakness to debilitating muscle weakness and pain that are resistant to treatment. Recent studies have demonstrated that physical activity is not only well tolerated by patients with IIMs but can have additional benefits as an adjuvant therapy to pharmacologic agents, especially if started early. However, to date, no study has investigated yoga as a potential adjunctive therapy for IIMs. This study aims to evaluate the effects of weekly yoga sessions as a new adjuvant therapy in patients with mild-to-moderate IIMs.
| Subjects and Methods|| |
To analyze the efficacy of yoga on IIMs, longitudinal cohorts who would be given supplementary weekly yoga therapy sessions in addition to their current pharmacologic treatment plans were recruited from an ambulatory setting rheumatology clinic. To be included in the study, patients had to be adults over the age of 18 years, diagnosed with mild-to-moderate IIMs (PM or DM) by a board-certified rheumatologist, willing to answer questionnaires and undergo manual muscle testing (MMT), not currently hospitalized, and not currently pregnant. Screening for the inclusion criteria was done by the rheumatologist following the patients at the time of the recruitment. All protocols and materials were approved by the institutional review board following human rights and in compliance with the Helsinki Declaration. Informed consent was obtained from all individual participants before the start of the study.
Two separate cohorts were created. The first cohort completed on-site yoga sessions, while the second cohort completed video-teleconference yoga sessions. All participants in both cohorts engaged in 8 weekly yoga sessions taught by the same yoga instructor. Patients were also given a list of movements they were to perform one other time per week at home [Appendix I].
A total of eight participants were recruited for the study: four participants for the on-site yoga cohort and four participants for the video-teleconference yoga cohort. Each participant was assessed twice: once before participating in any yoga therapy and once after completing the 8 weekly yoga sessions. Assessments consisted of the Myositis Activities Profile (MAP) questionnaire and the MMT. The MAP is a questionnaire that evaluated limitations in activities of daily living (ADL), with higher scores representing greater limitations. The MAP was the first disease-specific activity limitation questionnaire developed for people with inflammatory myositis. The MAP questionnaire is composed of four different categories of ADL - movement, activities of moving around, personal care and hygiene, and domestic activities. Meanwhile, the MMT is a series of physical tests performed by a trained physical therapist to evaluate the muscle strengths of three different muscle groups – axial, proximal, and distal, with higher scores representing greater muscle strength. Six participants' pre- and post-treatment MAP scores and four participants' pre- and post-treatment MMT scores were recorded and analyzed using the Wilcoxon signed-ranked test for statistically significant mean difference between the pre- and post-treatment MAP and MMT scores.
| Results|| |
Six participants' pre- and post-treatment MAP scores were collected and analyzed. Two participants ended up dropping out of the study, and thus their posttreatment MAP scores could not be collected. The average MAP score of the six participants before the initiation of the yoga adjuvant therapy was 66.67 with a standard deviation of 25.34. Meanwhile, the average posttreatment MAP score was 69.17 with a standard deviation of 30.71. Due to the small sample size (n = 6), the legitimacy of the normal distribution assumption could not be confirmed. The Wilcoxon signed-rank test indicated that, at 5% significance level, there were no significant differences between pre - and post-treatment MAP score, P value of 0.69.
Further analysis of the results from the MAP questionnaire was done based on the individual categories of ADL. [Figure 1] illustrates the number of participants who improved, worsened, or saw no effect for each category. Notable improvements occurred in categories of personal care and hygiene and domestic activities [Figure 1].
|Figure 1: Summary of Myositis Activities Profile questionnaire. Graph of the four categories that constitute the Myositis Activities Profile and the number of participants who improved, worsened, or saw no effect in each category post 8-weekly yoga sessions|
Click here to view
Four participants' pre- and post-treatment MMT scores were collected and analyzed. In addition to the two patients who dropped out of the study, two more patients' posttreatment MMT score could not be obtained due to the fact that the physical therapist performing the MMT relocated during the study period. The average MMT score of the four participants before the initiation of the yoga adjuvant therapy was 217.25 with a standard deviation of 41.65. Meanwhile, the average posttreatment MMT score was 228.25 with a standard deviation of 23.99. Again, due to the small sample size (n = 4), the legitimacy of the normal distribution assumption could not be confirmed. The Wilcoxon signed-rank test indicated that, at 5% significance level, there were no significant differences between the pre- and post-treatment MMT score, P value of 0.50.
Further analysis of the results from the MMT was done based on the individual categories of the muscle groups tested. [Figure 2] illustrates the number of participants who improved, worsened, or saw no effect for each muscle group. Notable improvements occurred in the proximal and distal muscle groups [Figure 2].
|Figure 2: Summary of Manual Muscle Test. Graph of the three muscle groups tested on the Manual Muscle Test and the number of participants who improved, worsened, or saw no effect for each muscle group post 8-weekly yoga sessions|
Click here to view
| Discussion|| |
Much remains unknown about the disease and how to best provide treatment for patients with IIMs. Only a limited number of large randomized clinical trials have been conducted for the treatment of IIMs. Early initiation of treatment, particularly within 6 months to 1 year from onset of symptoms, has been shown to lead to better outcomes. Currently, the standard armamentarium for autoimmune disease is used, with glucocorticoids and complementary immunosuppressive agents being favored as the first line of treatment. However, despite initial improvements, strong efforts are made to taper patients to their lowest tolerated dose of glucocorticoids due to the side effects associated with long-term corticosteroid use. Recently, the use of biologic agents such as rituximab, tocilizumab, and abatacept has become an area of intense interest as early results have shown favorable outcomes. However, biologic agents can be very costly, and despite the strides that have been made in the management, even with adequate treatment, many patients still experience decreased muscle endurance and strength as the disease progresses. Thus, a need exists for adjuvant therapeutic options.
The results of this study did not demonstrate statistically significant differences between pre- and post-yoga therapy. However, the hope is to highlight the potential benefits of yoga therapy beyond what was measured by the MAP and MMT and to increase awareness of yoga as an adjuvant therapy for IIMs. The results from this study demonstrated an 11-point increase in the average posttreatment MMT score, with a net increase in muscle strength in every category of the MMT. Despite seeing an increase in the average posttreatment MAP score, a closer analysis demonstrated net improvements in patients' ability to perform ADL in every category of the MAP questionnaire except for one – movement.
Interestingly, the benefits of yoga may be greater than what was reflected through the MAP and MMT scores. Yoga has been shown to lead to improvements in emotional, mental, and psychological well-being beyond what is expected from traditional aerobic and strength exercises., Furthermore, yoga has been shown to greatly improve gait, balance, flexibility, and pain. Finally, yoga may be particularly beneficial in the elderly, where limitations in mobility and exercise nonadherence are of major concerns. The ability of yoga to be modified to less demanding physical requirements lends itself to be recommended to more individuals with varying levels of physical capabilities.
It should be noted that there are clear limitations to this study. First, a limited number of participants who entered the study finished the 8-week protocol. Several efforts were made to recruit more participants, but they were ultimately unsuccessful. Despite starting with eight participants, two participants dropped out of the study before the completion of the study. In addition, the physical therapist performing the MMT relocated during the study period, leaving two more participants without posttreatment MMT scores. Thus, only six participants' pre- and post-treatment MAP scores and four participants' pre- and post-treatment MMT scores were analyzed. Another limitation was that the study period only consisted of 8 weekly yoga sessions. Thus, a generalization of the results is limited to short-term effects of yoga therapy.
Future studies should look to recruit a greater number of participants with easier to access virtual-yoga sessions, especially given the physical distance precautions in the COVID-19 era, as well as conducting the study for a longer time period to allow evaluation of the long-term effects of yoga therapy. Finally, additional assessment tools should be considered to get a more accurate assessment of the benefits offered by yoga therapy.
| Conclusions|| |
Physical activity is an important part of a healthy lifestyle. For patients with IIMs, long-term disability and physical inactivity due to pain and weakness are very common, especially in the later stages of the disease. Yoga has numerous theoretical benefits compared to aerobic and strength exercises and further studies into the effect of yoga on IIMs should be considered as a new alternative means of physical activity. To date, this is the first and only study to look into the effect of yoga on IIMs.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Lundberg IE, Miller FW, Tjärnlund A, Bottai M. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med 2016;280:39-51.
Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
Habers GE, Takken T. Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy – A systematic review. Rheumatology (Oxford) 2011;50:2113-24.
Baschung Pfister P, de Bruin ED, Bastiaenen CH, Maurer B, Knols RH. Reliability and validity of the german version of the myositis activities profile (MAP) in patients with inflammatory myopathy. PLoS One 2019;14:e0217173.
Baschung Pfister P, de Bruin ED, Sterkele I, Maurer B, de Bie RA, Knols RH, et al.
Manual muscle testing and hand-held dynamometry in people with inflammatory myopathy: An intra- and interrater reliability and validity study. PLoS One 2018;13:e0194531.
Fafalak RG, Peterson MG, Kagen LJ. Strength in polymyositis and dermatomyositis: Best outcome in patients treated early. J Rheumatol 1994;21:643-8.
Moghadam-Kia S, Oddis CV, Aggarwal R. Modern therapies for idiopathic inflammatory myopathies (IIMs): Role of biologics. Clin Rev Allergy Immunol 2017;52:81-7.
Postolova A, Chen JK, Chung L. Corticosteroids in myositis and scleroderma. Rheum Dis Clin North Am 2016;42:103-18, ix.
Oddis CV. Update on the pharmacological treatment of adult myositis. J Intern Med 2016;280:63-74.
Harris-Love MO. Physical activity and disablement in the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2003;15:679-90.
Bartlett SJ, Moonaz SH, Mill C, Bernatsky S, Bingham CO 3rd
. Yoga in rheumatic diseases. Current Rhe Repo 2013;15:387.
Wang Y, Lu S, Wang R, Jiang P, Rao F, Wang B, et al.
Integrative effect of yoga practice in patients with knee arthritis: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2018;97:e11742.
Roland KP, Jakobi JM, Jones GR. Does yoga engender fitness in older adults? A critical review. J Aging Phys Act 2011;19:62-79.
Schutzer KA, Graves BS. Barriers and motivations to exercise in older adults. Prev Med 2004;39:1056-61.
Cheung C, Park J, Wyman JF. Effects of yoga on symptoms, physical function, and psych?osocial outcomes in adults with osteoarthritis: A Focused review. Am J Phys Med Rehabil 2016;95:139-51.
Steve S Kong
Valdez St, Apt 635 Oakland, CA, 94612
Source of Support: None, Conflict of Interest: None
[Figure 1], [Figure 2]
|This article has been cited by|
||The effectiveness of yoga as a form of exercise in the management of rheumatic diseases
| ||Burhan Fatih Kocyigit, Zhaxybek Sagtaganov, Marlen Yessirkepov |
| ||Rheumatology International. 2023; |
|[Pubmed] | [DOI]|
||Harnessing the benefits of yoga for myositis, muscle dystrophies, and other musculoskeletal disorders
| ||Ahmad Saud, Maryam Abbasi, Holly Merris, Pranav Parth, Xaviar Michael Jones, Rohit Aggarwal, Latika Gupta |
| ||Clinical Rheumatology. 2022; |
|[Pubmed] | [DOI]|
| Article Access Statistics|
| Viewed||3075 |
| Printed||84 |
| Emailed||0 |
| PDF Downloaded||180 |
| Comments ||[Add] |
| Cited by others ||2 |